- Completed
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Updated: Jun 15, 2022
Bellini
RRMM
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)
NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in Multiple Myeloma
Suspended (Safety)
This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
Sponsor
AbbVie
Collaborator
Genentech, Inc.
Multiple locations
International study
ClinicalTrials.gov Identifier: NCT02755597
Official Title:A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
First Posted : April 29, 2016
Click here for details on ClinicalTrials.gov
Drug: Placebo
Drug: Bortezomib
Drug: Dexamethasone
Drug: Venetoclax
BELLINI
NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol; 2020
84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma
Hematology Disease Topics & Pathways:
Clinical Trials, Adults, Non-Biological, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies, Pharmacology, Study Population
Saturday, December 11, 2021: 10:30 AM
Learn more:
Locations
United States, Colorado
United States, North Carolina
United States, Ohio
Canada, Ontario
Canada, Quebec
Australia, New South Wales
Australia, Queensland
Australia, South Australia
Australia, Tasmania
Australia, Victoria
Australia, Western Australia
Europe
United Kingdom
France
Germany
Hungary
Ireland
Italy
Spain
Ukraine
South America
Brazil
Asia
Japan
Korea, Republic of
Russian Federation
Taiwan